Drug Target Models

Drug-target model

By Product Category

By Hot Target

Founded in 2018, Reqbio (Shanghai) Biotechnology Co., Ltd. is a comprehensive company specializing in proprietary biologics and contract research services for life sciences. Over the years, we have integrated resources and dedicated efforts to R&D, establishing a range of proprietary products and databases, including Drug Target Cell Libraries, Tracer Cell Libraries, and Gene Expression & Mutation Databases. Additionally, we have developed a suite of experimental CRO platforms covering gene editing, stable cell line generation, PCR detection, and NGS sequencing.
With innovation at the core of our strategy, we leverage cutting-edge cell function engineering technologies and a high-precision gene editing platform to build a comprehensive drug screening cell model system targeting key disease pathways such as kinases, GPCRs, and tumor immunology. We are committed to providing end-to-end support for global drug discovery, not only facilitating the development of novel targeted therapies but also advancing the understanding of cross-species gene functions and genetic drivers of human diseases. Building on these technological strengths, we continue to drive innovation in personalized molecular, cellular, and gene therapies.

By Product Category

GPCR Reporter Cells

Immunotherapy cells

Other Stable Cells

Assay Kits & Reagents

By Hot Target

Easily search for drug-target model related to popular research targets and find associated products.

GPCR Reporter Cells

Immunotherapy cells

Other Stable Cells

Assay Kits & Reagents

Class A（Rhodopsin）

The human GPCR family is classified into subclasses A (rhodopsin-like), B (secretin and adhesion), C (glutamate), and F (Frizzled) based on their amino acid sequences. Class A GPCRs, a family of rhodopsin-like receptors consisting of 719 members, are further divided into several subclasses: amines, peptides, proteins, lipids, melatonin, nucleotides, steroids, saccharocarboxylic acids, sensory receptors, and orphan receptors. Indications for Class A GPCRs include pain relief, allergies, cardiovascular diseases, hypertension, and cancer.

5-HTR ADORA1 ADORA2 ADORA3 ADRA1 ADRB2 AGTR1 APJ AVPR2 C3aR C5aR1 CB1 CB2 CCR1 CCR10 CCR2 CCR3 CCR4 CCR5 CCR6 CCR7 CCR8 CCR9 CHRM1 CHRM2 CHRM3 CHRM4 CHRM5 CRTH2 CX3CR1 CXCR1 CXCR2 CXCR3 CXCR4 CXCR5 CXCR6 CXCR7 DRD1 DRD2 DRD3 DRD4 DRD5 EDG1 EDNRA EDNRB FPR1 FPR2 FSHR GNRHR GPBAR1 GPR120 GPR174 GPR183 GPR34 GPR40 GPR43 GPR52 GPR54 HCAR1 LHCGR MAS1 MC4R MRGPR MRGPRX1 MRGPRX2 NK1R NK2R NK3R NMBR NPY1R NPY2R NPY4R NPY5R NTSR1 OPRD1（DOR） OPRK1（KOR） OPRL1（NOP） OPRM1（MOR） OX1R OX2R OXTR PTGER2 PTGER4 RXFP1 SSTR1 SSTR2 SSTR3 SSTR4 SSTR5 TAAR1 TSHR

Class B1（Secretin）

Class B GPCRs are divided into two subfamilies: B1 secretin receptors and B2 adhesion receptors. Members of the secretin receptor subfamily have large extracellular domains and bind to vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating peptide (PACAP), corticotropin-releasing factor (CRF), parathyroid hormone (PTH), growth hormone-releasing hormone (GHRH), calcitonin gene-related peptide (CGRP), glucagon, and glucagon-like peptide (GLP). The adhesion receptor subfamily has nine subclasses and possesses unique N-terminal motifs, such as epidermal growth factor, cadherin, and immunoglobulin domains.

CGRP1 CRF1R CRFR2 CTR GCGR GHRHR GIPR GLP1R GLP2R PAC1R PTH1R PTH2R SCTR VPAC1 VPAC2 XCR1

Class C（Glutamate）

Class C glutamate receptors contain 22 receptors, divided into 5 subfamilies, including 1 calcium-sensitive receptor (CaSR), 2 GABA type B receptors (GABAB1 and GABAB2), 3 taste 1 receptors (TS1R1-3), 8 metabolic glutamate receptors (mGluR1-8), and 8 orphan GPCRs.

CaSR GABA GPRC5D GRM4

Combination

CLP1R, GCGR, and GIPR are crucial drug targets for treating metabolic diseases. CLP1R is involved in regulating insulin secretion; GCGR plays a key role in glucose homeostasis and is a major target for diabetes drug development; GIPR mediates incretin effects and influences energy metabolism. Our company offers high-quality drug-target cells for these receptors, supporting high-throughput screening and activity validation to accelerate drug discovery for metabolic disorders.

GLP1R&GCGR GLP1R&GCGR&GIPR GLP1R&GIPR

Orphan and other 7TM

GPR55, GPR75, MRGPRB2, and other orphan or understudied 7-Transmembrane (7TM) receptors represent the "frontier" of novel drug discovery. They play crucial roles in key physiological and pathological processes such as neurobiology, metabolism, and immunity, offering vast untapped therapeutic potential.

GPR55 GPR75 MRGPRB2

Parental Cell

GPCRs (G protein-coupled receptors) are important proteins in cell signaling, with a topological conformation of seven transmembrane receptors. When an extracellular ligand acts on this receptor, the intracellular portion of the receptor binds to the G protein, activating the G protein and initiating different signal transduction pathways, leading to various biological effects.

Parental Cell

Combination

Our platform provides engineered cellular models covering multi-pathway combinations including PD-1, CTLA4, TIGIT, LAG3, 41BB, OX40, and SIRPα/CD47. Utilizing dual-reporter systems and antigen-presenting cell platforms, these models enable simultaneous evaluation of immune checkpoint synergy, antibody efficacy, and immune cell activation, offering physiologically relevant in vitro tools for developing combination immunotherapy.

PD1&CTLA4 PD1&TIGIT PDL1&CD155

Fc Effector

Designed for precise evaluation of key biological activities in antibody therapeutics. Our platform delivers standardized ADCC/ADCP reporter cells, comprehensively covering core mechanisms such as antibody-dependent cellular cytotoxicity and phagocytosis. These tools provide reliable solutions for antibody optimization and potency assessment.

ADCC/ADCP FcγR FcεRI

T Cell Activation

These engineered cellular models assess T cell activation through key signaling pathways. NFAT and NFκB reporter lines measure early transcriptional activity, while IL-2 secretion assays quantify functional cytokine output. Ideal for screening immunomodulators, bispecific antibodies, and CAR-T candidates, they deliver reliable, quantitative data for immunotherapy development.

Other TCE

Co-Stimulatory

Our platform provides reliable cellular tools for evaluating agonists targeting key co-stimulatory pathways. Available models include OX40, 4-1BB, GITR, CD27, HVEM/LIGHT, CD28, and BTLA, engineered with reporter systems to quantify pathway-specific activation. These standardized assays enable robust potency and efficacy assessment, accelerating the development of next-generation immunostimulatory therapeutics.

4-1BB BAFF BCMA CD27-CD70 CD28-CD80/86 CD40 DR3-TL1A GITR-GITRL HVEM-LIGHT ICOS-ICOSL ICOSL LTBR NCR1 NCR3 NKG2D-MIC OX40 PGLYRP1 TACI TMIGD2-HHLA2 TREM1 TREM2

Co-Inhibitory

Our platform provides comprehensive in vitro testing solutions for key co-inhibitory pathways, covering core targets including PD-1/PD-L1&L2, TIGIT/CD155, CTLA4, and LAG3, along with their common combinations. Utilizing standardized reporter cells and binding assays, we support activity evaluation, mechanism investigation, and drug screening for both single-target and dual immune checkpoint inhibitors, facilitating efficient development in cancer immunotherapy.

BTLA-HVEM CD160 CD161-CLEC2D CD200-CD200R CD96 CTLA4 HLA-G KIR2DL5A KIR2DL5B KIR3DL2 KIR3DL3-HHLA2 LAG3 LAIR1 LILRB1 LILRB2 LILRB4 NKG2A-HLA-E PD1-PDL1/2 PILR PVRIG-CD112 SIRPɑ-CD47 TIGIT-CD155 TIM-3 VISTA

Immune Checkpoint

We provide engineered cellular models targeting novel immune checkpoint molecules, including BDCA2, CD24, and VSIG4. These standardized reporter systems enable efficient evaluation of target activation/inhibition activity, supporting the screening and mechanistic study of immunomodulators. They offer reliable tools for drug development in cancer immunotherapy and autoimmune diseases.

BDCA2 CD24 VSIG4

STING

We offer specialized cellular tools for studying the Stimulator of Interferon Genes (STING) pathway, a critical target in cancer immunotherapy and antiviral research. Our assays enable precise evaluation of STING agonist activity, cyclic dinucleotide sensing, and downstream interferon response, supporting the development of novel immunotherapeutics.

Other

Cytokine&Growth Factor

Our comprehensive testing platform offers validated cellular assays for a wide range of cytokines and growth factors, including BCMA, TGFβ, EGF, CSF1R, and key interleukins (e.g., IL2, IL4/13, IL6). We also support pathways such as IFN signaling, RANKL, VEGF, Wnt, and TSLP. These ready-to-use, standardized assays enable sensitive and quantitative evaluation of ligand activity, receptor engagement, and pathway modulation to accelerate drug discovery and development.

Activin BNP/NPR1 c-KIT CSF1R EGFR EPO ERBBs FGF21/KLB FGFR FGFR1 FGFR2 GDF GHR GM-CSF IFN IGF1R IL1 IL10 IL11 IL12 IL17/IL25 IL18 IL19/IL20/IL22/IL24 IL2/IL15 IL21 IL23 IL27 IL3 IL31 IL33 IL36 IL4/IL13 IL5 IL6 IL7 IL9 Insulin Integrin NGF Notch1 NPR2 OSMR PDGF PRL RANK-RANKL TGF-β1 TIE2 TNFα TPO-TPOR TRKB TSLP VEGF WNT

TAA

We offer standardized cellular models covering a broad range of tumor-associated antigens (TAAs), including key targets such as 5T4, B7H3, CD123, CD19, CD20, CD22, CD30, CD33, and CD38. This platform supports in vitro activity evaluation and screening for antibody drugs, CAR-T therapies, and bispecific antibodies, providing efficient and reliable detection tools for cancer immunotherapy development.

5T4 ACP3 ADAM9 ASCT2 B7H3 B7H4 CD123 CD147 CD166 CD19 CD2 CD20 CD22 CD228 CD30 CD33 CD38 CD4 CD44 CD46 CD54 CD56 CD7 CD73 CD8 CD94 CD99 CDCP1 CDHs CEACAMs CLDN18.2 CLDN6 CLDNs DDR1 DLK1 DLL3 ENPP3 EрCAM FAP FCRL5 FRα GPC1 GPC3 GPC33 GUCY2C HLA0201 KLK2 LRRC15 LY6E LY6G6D MERTK MET MSLN MUCs Nectin4 PRAME /HLA0201 PSMA PTK7 ROR1 ROR2 SEZ6 SLC34A2 SLC39A6 SLITRK6 SORT1 STEAP1 STEAP1B2 STEAP2 TF TFRC TM4SF1 TREM2 TROP2

TLR

We provide engineered reporter cells covering key innate immune receptors, including TLR2, TLR3, TLR4, TLR5, TLR7, TLR8, and TLR9. This platform enables efficient detection of ligand-induced activation, supporting agonist/antagonist screening, vaccine adjuvant evaluation, and innate immune pathway research. It serves as a standardized tool for drug discovery in infectious diseases, oncology, and autoimmune disorders.

TLR2 TLR3 TLR4 TLR5 TLR7 TLR8 TLR9

Signaling pathway cells

Tracer Cell

Nuclear Receptor

Ion Channel

MUSK

Transporter

Other

Assay Kits

Reagents

Committed to providing comprehensive support for global drug development